Mumbai, India (February 23, 2025) – Nutriventia, a pioneer in consumer-centric nutraceutical innovations, today announced the results of a new clinical trial evaluating its patented TurmXTRA™ 60N, a low-dose, water-dispersible turmeric extract, for the management of mild-to-moderate knee osteoarthritis (OA).

According to Rajat Mittal Shah, Co-founder, Nutriventia, “TurmXTRA™ 60N has consistently been studied in joint and muscle health for healthy individuals. This marks our first clinical study in individuals with mild-to-moderate osteoarthritis, and we are encouraged by the significant improvements observed with just a small daily dose. TurmXTRA™ 60N was designed to reduce pill burden while delivering clinically meaningful benefits, and these findings further validate its potential in supporting joint health.”

The study evaluated the effects of 250mg daily of TurmXTRA™ 60N compared to a placebo in individuals with mild-to-moderate knee OA. The study has been peer-reviewed and published in the Journal of Pain Research.

Study Highlights:

• Early & Sustained Joint Comfort: Participants taking TurmXTRA™ 60N reported improved joint comfort as early as day 7, with a significantly higher mean reduction in VAS score from baseline to day 90 compared to the placebo group.
• Enhanced Knee Function: Participants taking TurmXTRA™ 60N showed significant improvement in Knee injury and Osteoarthritis Outcome Score (KOOS) across all domains (pain, symptoms, activities of daily living, function in sport and recreation, and knee-related quality of life) on Day 90 compared to the placebo group.
• Favorable Biological Response: The study also observed positive changes in key biological indicators associated with joint health over 90 days in participants taking TurmXTRA™ 60N, suggesting potential benefits in supporting joint resilience over time.

“These findings reinforce the potential of TurmXTRA™ 60N as a convenient and effective option for managing musculoskeletal health,” said Dr Shefali, noting that “with positive results in mild to moderate osteoarthritis, TurmXTRA™ 60N has shown promise as a potential agent for improving joint mobility and functionality, which is crucial for individuals across all age groups. Notably, these benefits have been observed consistently in clinical settings with a single daily dose, making it a convenient option that may enhance compliance.”

About the Study:

The randomized, double-blind, placebo-enrolled 139 participants aged 45-75 years with mild-to-moderate knee OA. Participants were randomly assigned to receive either TurmXTRA™ 60N (250 mg) or a placebo daily for three months. Pain intensity was assessed using the visual analog scale (VAS), and knee function was evaluated using the Knee injury and Osteoarthritis Outcome Score (KOOS) questionnaire. Biological markers related to joint health were also analyzed over the study period.